Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Current Leases (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Current Leases data on record, last reported at $408122.0 in Q4 2025.

  • For Q4 2025, Current Leases fell 2.76% year-over-year to $408122.0; the TTM value through Dec 2025 reached $408122.0, down 2.76%, while the annual FY2025 figure was $435507.0, 37.04% up from the prior year.
  • Current Leases reached $408122.0 in Q4 2025 per INM's latest filing, down from $424765.0 in the prior quarter.
  • Across five years, Current Leases topped out at $435507.0 in Q2 2025 and bottomed at $82232.0 in Q3 2021.
  • Average Current Leases over 5 years is $375450.9, with a median of $404219.5 recorded in 2022.
  • Peak YoY movement for Current Leases: soared 391.49% in 2022, then fell 27.5% in 2023.
  • A 5-year view of Current Leases shows it stood at $391805.0 in 2021, then grew by 5.74% to $414307.0 in 2022, then fell by 12.1% to $364190.0 in 2023, then increased by 15.25% to $419711.0 in 2024, then decreased by 2.76% to $408122.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $408122.0 in Q4 2025, $424765.0 in Q3 2025, and $435507.0 in Q2 2025.